<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159626</url>
  </required_header>
  <id_info>
    <org_study_id>A9131010</org_study_id>
    <nct_id>NCT01159626</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Subject- and Investigator-blind, Sponsor-open, Placebo-controlled, Single- and Multiple-dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of PF-03463275 in Healthy Male Japanese and Western Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is the first clinical trial in Japanese subjects. The study is designed to
      evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of
      PF-03463275 oral controlled release formulation in Japanese and Western male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events monitoring</measure>
    <time_frame>Day 0 to Day 4 in each period of Cohort A, Day 0 to Day 10 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs, ECGs, clinical laboratory tests, clinical evaluations and examinations, suicidality assessment</measure>
    <time_frame>Screening and Day 0 to Day 4 in each period of Cohort A, Screening and Day 0 to Day 10 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum (after single dose): Cmax, AUClast, AUCtau (Calculated only in Cohort B) and as data permit Tmax, AUCinf, t1/2</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A, Day 1 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum (after multiple dose): Ctrough, Cmax*, AUCtau* and as data permit Tmax*, t1/2* and Rac* (accumulation ratio) * Calculated only after the last administration.</measure>
    <time_frame>Day 2 to Day 10 in Cohort B</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <description>Oral single 20 mg dose as two 10mg controlled release tablets</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <description>Oral single 40 mg dose as four 10mg controlled release tablets</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <description>Oral single 60 mg dose as six 10mg controlled release tablets</description>
    <arm_group_label>Single dose</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral single dose as matching placebo</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-03463275</intervention_name>
    <description>Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days</description>
    <arm_group_label>Multiple dose</arm_group_label>
    <other_name>Not Specified</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral multiple doses as matching placebo for 7 days</description>
    <arm_group_label>Multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2, and a total body weight &gt;50 kg (110 lbs).

          -  Japanese subjects must have four Japanese grandparents who were born in Japan.

        Exclusion Criteria:

          -  Subjects that are genotyped to be PM (poor metabolizer), UM (ultrarapid metabolizer),
             IM/EM and EM/UM for CYP2D6 status.

          -  Evidence or history of clinically significant hematological (including anemia), renal,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurologic, or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at time of dosing).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9131010&amp;StudyName=Pharmacokinetics%2C%20Safety%20and%20Tolerability%20Study%20of%20PF-03463275%20in%20Healthy%20Male%20Japanese%20and%20Western%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Phase1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Male</keyword>
  <keyword>Japanese</keyword>
  <keyword>Schizophrenia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

